Sustained very low disease activity and remission in psoriatic arthritis patients
<p><strong>Introduction:</strong><br /> Sustained remission should be considered the main therapeutic target in psoriatic arthritis (PsA). Very low disease activity (VLDA) and a DAPSA score ≤ 4 are the most commonly used criteria. The aim of the present study was to evaluate...
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Journal article |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
Springer
2019
|
| _version_ | 1826313628486205440 |
|---|---|
| author | Lubrano, E Perrotta, F Scriffignano, S Coates, L Helliwell, P |
| author_facet | Lubrano, E Perrotta, F Scriffignano, S Coates, L Helliwell, P |
| author_sort | Lubrano, E |
| collection | OXFORD |
| description | <p><strong>Introduction:</strong><br />
Sustained remission should be considered the main therapeutic target in psoriatic arthritis (PsA). Very low disease activity (VLDA) and a DAPSA score ≤ 4 are the most commonly used criteria. The aim of the present study was to evaluate the rate of sustained remission in a group of PsA patients followed in a real-life setting.</p><br />
<p><strong>Methods:</strong><br />
All PsA patients satisfying CASPAR criteria were followed prospectively every 3–6 months, in a context of clinical practice by January 2013. Sustained remission was defined when patients achieved a DAPSA score ≤ 4 and/or VLDA for at least 12 months. The exclusion criterion was the presence of a condition of VLDA or DAPSA ≤ 4 at the baseline assessment. Kaplan–Meier survival curve was used to evaluate the survival of patients.</p><br />
<p><strong>Results:</strong><br />
A total of 147 PsA patients were evaluated for the study. Of these, 80 performed at least 12 consecutive months of follow-up. The average duration of follow-up was 24 months (range, 12–60 months). At the last follow-up, 22 patients were on csDMARDs treatment while 58 patients were on bDMARDs. Of the 80 patients, 14 (17.5%) achieved a sustained VLDA while 24 (30%) achieved sustained remission according to the DAPSA criteria. The mean duration of remission in patients achieving VLDA and DAPSA ≤ 4 was 17 months for both criteria. High baseline levels of CRP, shorter disease duration, and less pain at baseline were found to be predictors of sustained VLDA and DAPSA remission.</p><br />
<p><strong>Conclusions:</strong><br />
In our study, based on clinical practice, a sustained VLDA was achieved in 17.5% and a sustained remission according to the DAPSA criteria in 30% of patients with PsA.ith PsA.</p> |
| first_indexed | 2024-03-07T05:02:27Z |
| format | Journal article |
| id | oxford-uuid:d8c14159-0ef9-4dad-9ed0-7503a77a6265 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:16:08Z |
| publishDate | 2019 |
| publisher | Springer |
| record_format | dspace |
| spelling | oxford-uuid:d8c14159-0ef9-4dad-9ed0-7503a77a62652024-07-20T14:40:11ZSustained very low disease activity and remission in psoriatic arthritis patientsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d8c14159-0ef9-4dad-9ed0-7503a77a6265EnglishSymplectic Elements at OxfordSpringer2019Lubrano, EPerrotta, FScriffignano, SCoates, LHelliwell, P<p><strong>Introduction:</strong><br /> Sustained remission should be considered the main therapeutic target in psoriatic arthritis (PsA). Very low disease activity (VLDA) and a DAPSA score ≤ 4 are the most commonly used criteria. The aim of the present study was to evaluate the rate of sustained remission in a group of PsA patients followed in a real-life setting.</p><br /> <p><strong>Methods:</strong><br /> All PsA patients satisfying CASPAR criteria were followed prospectively every 3–6 months, in a context of clinical practice by January 2013. Sustained remission was defined when patients achieved a DAPSA score ≤ 4 and/or VLDA for at least 12 months. The exclusion criterion was the presence of a condition of VLDA or DAPSA ≤ 4 at the baseline assessment. Kaplan–Meier survival curve was used to evaluate the survival of patients.</p><br /> <p><strong>Results:</strong><br /> A total of 147 PsA patients were evaluated for the study. Of these, 80 performed at least 12 consecutive months of follow-up. The average duration of follow-up was 24 months (range, 12–60 months). At the last follow-up, 22 patients were on csDMARDs treatment while 58 patients were on bDMARDs. Of the 80 patients, 14 (17.5%) achieved a sustained VLDA while 24 (30%) achieved sustained remission according to the DAPSA criteria. The mean duration of remission in patients achieving VLDA and DAPSA ≤ 4 was 17 months for both criteria. High baseline levels of CRP, shorter disease duration, and less pain at baseline were found to be predictors of sustained VLDA and DAPSA remission.</p><br /> <p><strong>Conclusions:</strong><br /> In our study, based on clinical practice, a sustained VLDA was achieved in 17.5% and a sustained remission according to the DAPSA criteria in 30% of patients with PsA.ith PsA.</p> |
| spellingShingle | Lubrano, E Perrotta, F Scriffignano, S Coates, L Helliwell, P Sustained very low disease activity and remission in psoriatic arthritis patients |
| title | Sustained very low disease activity and remission in psoriatic arthritis patients |
| title_full | Sustained very low disease activity and remission in psoriatic arthritis patients |
| title_fullStr | Sustained very low disease activity and remission in psoriatic arthritis patients |
| title_full_unstemmed | Sustained very low disease activity and remission in psoriatic arthritis patients |
| title_short | Sustained very low disease activity and remission in psoriatic arthritis patients |
| title_sort | sustained very low disease activity and remission in psoriatic arthritis patients |
| work_keys_str_mv | AT lubranoe sustainedverylowdiseaseactivityandremissioninpsoriaticarthritispatients AT perrottaf sustainedverylowdiseaseactivityandremissioninpsoriaticarthritispatients AT scriffignanos sustainedverylowdiseaseactivityandremissioninpsoriaticarthritispatients AT coatesl sustainedverylowdiseaseactivityandremissioninpsoriaticarthritispatients AT helliwellp sustainedverylowdiseaseactivityandremissioninpsoriaticarthritispatients |